Glucocorticoids <i>vs</i> glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis without poor-prognosis factors: a target trial emulation study

This study shows that the adjunction of CYC to GCs does not reduce the risk of relapse in patients with EGPA and no poor-prognosis factors. It supports current guidelines in patients without severe manifestations but challenges the need of CYC adjunction in patients with severe manifestations but no poor-prognosis factors.

Authors

Institutions

Publication Details

Journal
Lara D. Veeken
Published
2025-05-24
DOI
https://doi.org/10.1093/rheumatology/keaf256
Citations
2
Primary Topic
Eosinophilic Disorders and Syndromes
Type
article
Field-Weighted Citation Impact
3.34
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Glucocorticoids vs glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis without poor-prognosis factors: a target trial emulation study

Claudia Feder, Arianna Troilo, Maria Letizia Urban, Cécile‐Audrey Durel et al.
2 citations
Lara D. Veeken
Eosinophilic Disorders and Syndromes
3.34
article

Glucocorticoids vs glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis without poor-prognosis factors: a target trial emulation study

Claudia Feder, Arianna Troilo, Maria Letizia Urban, Cécile‐Audrey Durel, Nils Venhoff, Bernard Bonnotte, Vítor Teixeira, Luc Mouthon, Claus Kroegel, Michele Iudici, Maxime Samson, Thomas Barba, Carlomaurizio Montecucco, Jens Thiel, Jean‐Emmanuel Kahn, Augusto Vaglio, Benjamin Seeliger, Chiara Marvisi, Matthieu Groh, Thomas Neumann, Boris Sorin, Xavier Puéchal, Raphaël Porcher, Giacomo Emmi, Franco Schiavon, Giulia Cassone, David R.W. Jayne, Francesco Locatelli, Renato Alberto Sinico, Juliane Mahrhold, Sara M. Monti, Bernhard Hellmich, Benjamin Terrier, Carlo Salvarani, Loïc Guillevin, Matthias Papo
article en
2 citations

Abstract

This study shows that the adjunction of CYC to GCs does not reduce the risk of relapse in patients with EGPA and no poor-prognosis factors. It supports current guidelines in patients without severe manifestations but challenges the need of CYC adjunction in patients with severe manifestations but no poor-prognosis factors.

Lara D. VeekenVol. 64(10)
University of Modena and Reggio Emilia (IT), University of Padua (IT), Université de Versailles Saint-Quentin-en-Yvelines (FR), Université Paris Cité (FR), University of Cambridge (GB), University of Pavia (IT), Dialog Semiconductor (Germany) (DE), Kantonsspital St. Gallen (CH), University Medical Center Freiburg (DE), Hotel Dieu Hospital (CA), Medizinische Hochschule Hannover (DE), Azienda Sanitaria Unità Locale di Reggio Emilia (IT), Hôpital Cochin (FR), Assistance Publique – Hôpitaux de Paris (FR), Meyer Children's Hospital (IL), University Hospital of Geneva (CH), Administração Regional de Saúde de Lisboa e Vale do Tejo (PT), Meyer Children's Hospital (IT), Université Bourgogne Franche-Comté (FR), Algarve Biomedical Center (PT), Hôpital Edouard Herriot (FR), Hôtel-Dieu de Paris (FR), Jena University Hospital (DE), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Hôpital Foch (FR), IRCCS Humanitas Research Hospital (IT), University of Florence (IT), Geneva College (US), University of Algarve (PT)
No poverty
Openalex Percentile: Top 9%
Eosinophilic Disorders and Syndromes
3.34
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.